TY - JOUR
T1 - Stuttering priapism
T2 - Insights into pathogenesis and management
AU - Morrison, Belinda F.
AU - Burnett, Arthur L.
N1 - Funding Information:
Disclosures B. Morrison: none. Dr. Arthur Burnett has served as a board member for Abbott, Auxilium, and Endo Pharmaceuticals, and has received grants from the National Institutes of Health.
PY - 2012/8
Y1 - 2012/8
N2 - Priapism is defined as a persistent, painful erection that continues beyond, or is unrelated to, sexual stimulation. It may be categorized as either ischemic (low/absent flow) or nonischemic (high flow). Stuttering priapism is a variant of the ischemic type that is characterized by repetitive, transient, painful, self-limiting episodes of priapism. It is associated with various hematological disorders, including sickle cell disease and pharmacological treatments. The consequences of ineffective treatment of priapism are erectile dysfunction and impaired quality of life due to chronic pain and physical disfigurement. Many of the existing medical therapeutic options for treatment of stuttering priapism are nonmechanistic and associated with significant adverse effects. However, the scientific knowledge of stuttering priapism has transitioned in the past few years, from a condition that is poorly understood to one that has borne a burst of evolving molecular science. In this review, the pathophysiology of priapism is discussed, with particular emphasis on new molecular effectors and mechanisms. Novel treatment methods, as well as potential future agents, based on the emerging molecular evidence are discussed.
AB - Priapism is defined as a persistent, painful erection that continues beyond, or is unrelated to, sexual stimulation. It may be categorized as either ischemic (low/absent flow) or nonischemic (high flow). Stuttering priapism is a variant of the ischemic type that is characterized by repetitive, transient, painful, self-limiting episodes of priapism. It is associated with various hematological disorders, including sickle cell disease and pharmacological treatments. The consequences of ineffective treatment of priapism are erectile dysfunction and impaired quality of life due to chronic pain and physical disfigurement. Many of the existing medical therapeutic options for treatment of stuttering priapism are nonmechanistic and associated with significant adverse effects. However, the scientific knowledge of stuttering priapism has transitioned in the past few years, from a condition that is poorly understood to one that has borne a burst of evolving molecular science. In this review, the pathophysiology of priapism is discussed, with particular emphasis on new molecular effectors and mechanisms. Novel treatment methods, as well as potential future agents, based on the emerging molecular evidence are discussed.
KW - Androgen
KW - Erectile dysfunction
KW - Erection
KW - Ischemicpriapism
KW - Nitric oxide
KW - Penis
KW - Phosphodiesterase type 5
KW - Priapism
KW - Sicklecelldisease
KW - Stuttering priapism
UR - http://www.scopus.com/inward/record.url?scp=84864844050&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864844050&partnerID=8YFLogxK
U2 - 10.1007/s11934-012-0258-9
DO - 10.1007/s11934-012-0258-9
M3 - Review article
C2 - 22648304
AN - SCOPUS:84864844050
SN - 1527-2737
VL - 13
SP - 268
EP - 276
JO - Current Urology Reports
JF - Current Urology Reports
IS - 4
ER -